Maypharm Co., Ltd. has created the Hyalmass Aqua-Exosome, a hybrid filler.
Rido at Adobe Stock
Maypharm Co., Ltd., a medical and dermo-cosmetic product manufacturer based in South Korea, has created the Hyalmass Aqua-Exosome, a hybrid filler. The filler combines hyaluronic acid, exosomes and PDRNa (polydeoxyribonucleotide) to address skin hydration, elasticity and regeneration, according to a Dec. 30 press release.
The Hyalmass Aqua-Exosome filler is packaged in prefilled syringes, according to the release, and stimulates fibroblasts to produce collagen and elastin in the skin.
To create the hybrid filler, Maypharm Co. partnered with Beauty Factory, a Korean medical aesthetics manufacturer, per the release.
FOOTNOTE:
aA drug derived from Salmon DNA used for its regenerative and healing properties
